

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

DUSA PHARMACEUTICALS INC

Form 4

June 28, 2001

FORM 4

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. SEE Instruction 1(b).

OMB Number: 3235-0287
Estimated average burden hours per response 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person*

Cooper Hill Partners, L.P.

(Last) (First) (Middle)

230 Park Avenue

(Street)

New York, NY 10169

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

DUSA Pharmaceuticals Inc. DUSA

3. IRS or Social Security Number of Reporting Person (Voluntary)

4. Statement for Month/Year

5/01

5. If Amendment, Date of Original (Month/Year)

6. Relationship of Reporting Person(s) to Issuer (Check all applicable)

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

- Director
- 10% Owner
- Officer (give title below)
- Other (specify below)

 7. Individual or Joint/Group Filing (Check Applicable Line)

- Form filed by One Reporting Person
 - Form filed by More than One Reporting Person
-

TABLE I--NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED

1. Title of Security (Instr. 3)	2. Trans- action Date (Month/ Day/ Year)	3. Trans- action Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Amount	(A) or (D)	Price
		Code V				
Common Stock, par value \$.01 per share	4/4/01	P	74,000	(A)		\$11.3125
Common Stock, par value \$.01 per share	5/16/01	P	9,600	(A)		\$13.52
Common Stock, par value \$.01 per share	5/29/01	P	18,900	(A)		\$12.10
Common Stock, par value \$.01 per share	6/4/01	P	4,600	(A)		\$11.70

5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
399,500	(I)	See Explanation of Responses

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

10. Ownership	11. Nature of
Form of	Indirect
Derivative	Beneficial
Security:	Ownership
Direct (D) or	(Instr. 4)
Indirect (I)	
(Instr. 4)	

Explanation of Responses

Pursuant to an investment advisory contract, Cooper Hill Partners, L.P. currently has the power to vote and dispose of the securities held for the account of CLSP Overseas, Ltd. and, accordingly, may be deemed the "beneficial owner" of such securities. Mr. Casdin is the managing member of Casdin Capital, LLC, the general partner of Cooper Hill Partners, L.P.

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this form, one of which must be manually signed. If space is insufficient, SEE Instruction 6 for procedure.

/s/ Jeffrey Casdin	6/27/01

By: Jeffrey Casdin	Date
For Casdin Capital, LLC,	
General Partner of Cooper Hill	
Partners, L.P., Investment Manager	
of CSLP Overseas, Ltd.,	
and Individually	
**Signature of Reporting Person	